Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-05-31-Speech-3-171"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20060531.16.3-171"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Madam President, Commissioner, ladies and gentlemen, the organisation of healthcare in the Member States is based upon solidarity through hospital networks, social security systems and mutual insurance schemes. The pharmaceutical industry, however, selects its patients on the basis of their resources – I am thinking of the diseases of poor countries – or on the basis of the numbers of patients involved. That is why we now have to legislate on the question of medicinal products for paediatric use.
We welcome the fact that this report will be adopted tomorrow, as we all want children to have medication appropriate to their age and medical condition without delay. Having said that, I regret – and Mrs Grossetête has also pointed this out – that the two-year period for marketing a medicinal product has been maintained, and, moreover, I regret that the amendment intended to cut that period has not been supported. I also regret the long delay in obtaining an inventory of needs for paediatric treatments. These delays belie the declarations of urgency made here in Parliament.
Finally, in relation to the provisions on risk management and pharmacovigilance, we must be careful to ensure they are properly implemented and, if necessary, be ready to amend our text."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples